Human papillomavirus seroprevalence and seroconversion following baseline detection of nine human papillomavirus types in young women

IF 4.7 Q1 VIROLOGY

Tumour Virus Research Pub Date : 2022-06-01 DOI:10.1016/j.tvr.2022.200236

Darron R. Brown , Xavier Castellsagué , Daron Ferris , Suzanne M. Garland , Warner Huh , Marc Steben , Cosette M. Wheeler , Alfred Saah , Alain Luxembourg , Se Li , Christine Velicer

{"title":"Human papillomavirus seroprevalence and seroconversion following baseline detection of nine human papillomavirus types in young women","authors":"Darron R. Brown , Xavier Castellsagué , Daron Ferris , Suzanne M. Garland , Warner Huh , Marc Steben , Cosette M. Wheeler , Alfred Saah , Alain Luxembourg , Se Li , Christine Velicer","doi":"10.1016/j.tvr.2022.200236","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Estimates of the humoral immune response to incident human papillomavirus (HPV) infections are limited.</p></div><div><h3>Methods</h3><p>In this post hoc analysis of 3875 women aged 16–23 years from a 4-valent HPV vaccine trial (NCT00092482), HPV seroprevalence on day 1 was measured with a 9-valent HPV (HPV 6/11/16/18/31/33/45/52/58) competitive Luminex immunoassay and compared with cervical/external genital HPV detection by polymerase chain reaction. In the control group, among women who were HPV DNA‒negative on day 1, seroconversion following initial HPV detection was estimated using Kaplan-Meier methods.</p></div><div><h3>Results</h3><p>Type-specific HPV seropositivity among women with no day 1 cervical/external genital HPV detection was 0.6%–3.6%. Women with any 9-valent HPV (9vHPV) cervical/external genital detection (796/3875; 20.5%) had concordant seropositivity ranging from 13.4% (HPV 45) to 38.5% (HPV 6). Among women in the control group who were negative for all HPV types on day 1, seroconversion by month 30 after initial detection ranged from 29% (HPV 45) to 75% (HPV 16).</p></div><div><h3>Conclusions</h3><p>Humoral immune response to HPV is variable and dynamic, depending on type-specific exposure. This longitudinal analysis provides insight into the relationship between incident infection and seropositivity.</p><p>ClinicalTrials.gov; NCT00092482 <span>https://clinicaltrials.gov/ct2/show/NCT00092482</span><svg><path></path></svg>.</p></div>","PeriodicalId":52381,"journal":{"name":"Tumour Virus Research","volume":null,"pages":null},"PeriodicalIF":4.7000,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666679022000027/pdfft?md5=0be29c852fae3e60322d14eb99785045&pid=1-s2.0-S2666679022000027-main.pdf","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tumour Virus Research","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666679022000027","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"VIROLOGY","Score":null,"Total":0}

引用次数: 2

Abstract

Background

Estimates of the humoral immune response to incident human papillomavirus (HPV) infections are limited.

Methods

In this post hoc analysis of 3875 women aged 16–23 years from a 4-valent HPV vaccine trial (NCT00092482), HPV seroprevalence on day 1 was measured with a 9-valent HPV (HPV 6/11/16/18/31/33/45/52/58) competitive Luminex immunoassay and compared with cervical/external genital HPV detection by polymerase chain reaction. In the control group, among women who were HPV DNA‒negative on day 1, seroconversion following initial HPV detection was estimated using Kaplan-Meier methods.

Results

Type-specific HPV seropositivity among women with no day 1 cervical/external genital HPV detection was 0.6%–3.6%. Women with any 9-valent HPV (9vHPV) cervical/external genital detection (796/3875; 20.5%) had concordant seropositivity ranging from 13.4% (HPV 45) to 38.5% (HPV 6). Among women in the control group who were negative for all HPV types on day 1, seroconversion by month 30 after initial detection ranged from 29% (HPV 45) to 75% (HPV 16).

Conclusions

Humoral immune response to HPV is variable and dynamic, depending on type-specific exposure. This longitudinal analysis provides insight into the relationship between incident infection and seropositivity.

ClinicalTrials.gov; NCT00092482 https://clinicaltrials.gov/ct2/show/NCT00092482.

查看原文本刊更多论文

年轻女性九种人乳头瘤病毒基线检测后的人乳头瘤病毒血清阳性率和血清转化

背景:关于人乳头瘤病毒(HPV)感染的体液免疫反应的估计是有限的。方法采用9价HPV (HPV 6/11/16/18/31/33/45/52/58)竞争性Luminex免疫分析法对3875名年龄在16-23岁的4价HPV疫苗试验(NCT00092482)进行事后分析，测定第1天的HPV血清阳性率，并与聚合酶链反应检测宫颈/外生殖器HPV进行比较。在对照组中，在第1天HPV dna阴性的妇女中，使用Kaplan-Meier方法估计初次HPV检测后的血清转化。结果未进行第1天宫颈/外生殖器HPV检测的妇女中HPV类型特异性血清阳性为0.6% ~ 3.6%。患有任何9价HPV (9vHPV)宫颈/外生殖器检测的妇女(796/3875;20.5%)有一致的血清阳性，范围从13.4% (HPV 45)到38.5% (HPV 6)。在对照组中，在第1天所有HPV类型均为阴性的女性，在首次检测后的第30个月，血清转化范围从29% (HPV 45)到75% (HPV 16)。结论人乳头瘤病毒的免疫反应是可变的、动态的，取决于类型特异性暴露。这种纵向分析提供了对偶发感染和血清阳性之间关系的深入了解。NCT00092482 https://clinicaltrials.gov/ct2/show/NCT00092482。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Tumour Virus Research Medicine-Infectious Diseases

CiteScore

6.50

自引率

2.30%

发文量

审稿时长

56 days